Semax vs Selank compared across sequence, mechanism, half-life, registered indications and depth of evidence — and where the shared Pro-Gly-Pro design stops being a shared mechanism.
Semax and Selank are the two best-known members of a small family of Russian regulatory peptides, and they are routinely discussed as interchangeable "nootropic nasal peptides." They are not. They share a design trick and a country of origin; their targets, their registered indications, and the shape of their evidence differ.
Both compounds came out of the Institute of Molecular Genetics of the Russian Academy of Sciences, from work associated with Nikolai Myasoedov's group — Selank in collaboration with the Zakusov Research Institute of Pharmacology.
Both are built the same way: take a short, biologically active natural fragment that the body degrades almost instantly, and bolt Pro-Gly-Pro onto the C-terminus. The proline-rich tail slows proteolysis and confers activity of its own, since PGP is a released metabolite with reported effects in brain tissue.
The starting fragments are what diverge. Semax is Met-Glu-His-Phe-Pro-Gly-Pro — the Met-Glu-His-Phe core of the ACTH(4-10) melanocortin fragment, plus the tail. Critically, it retains the fragment's neurotropic behaviour without the corticotropic one: it is not studied as a stimulus to adrenal steroid release. Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro — tuftsin, a tetrapeptide derived from the IgG heavy chain with immunomodulatory roles, plus the same tail. Selank therefore inherits an immune lineage that Semax does not.
| Semax | Selank | |
|---|---|---|
| Sequence | Met-Glu-His-Phe-Pro-Gly-Pro | Thr-Lys-Pro-Arg-Pro-Gly-Pro |
| Parent fragment | ACTH(4-10) melanocortin fragment | Tuftsin (IgG-derived immunopeptide) |
| Primary research axis | Neurotrophic — BDNF/NGF expression, neuroprotection | Anxiolytic — GABAergic and serotonergic modulation |
| Secondary lines | Attention, cognition, ischaemic injury, optic nerve | Immunomodulation, enkephalin turnover, stress response |
| Plasma half-life | Minutes; human PK data thin | Minutes; human PK data thinner still |
| Usual research route | Intranasal (0.1% / 1% solutions in the literature) | Intranasal (0.15% solution) |
| Russian registration | Cerebrovascular events, post-stroke recovery, cognition/attention disorders | Generalised anxiety disorder; adjunct in neurasthenia (approved 2009) |
| Depth of human data | Larger clinical dataset, stroke-dominated | Smaller; a handful of anxiety trials |
| Independent Western replication | Limited | Very limited |
The most-replicated preclinical finding is upregulation of BDNF and NGF expression in the hippocampus and cortex following intranasal administration, with downstream effects on synaptic plasticity markers and on learning endpoints in rodents. Semax also shifts inflammatory gene expression after experimental ischaemia, which is the mechanistic bridge to its registered indication.
Its human dataset is dominated by Russian ischaemic-stroke work, where administration in the acute window has been reported to raise circulating BDNF and to improve functional recovery scores. That literature is the largest human dataset for either compound — and it is also the clearest illustration of the problem with both: it was generated, published, and reviewed almost entirely within one regulatory system, frequently without the blinding, placebo control, and pre-registration that Western regulators expect. It has never been submitted to the FDA or EMA.
Selank's headline claim is anxiolysis without sedation, cognitive blunting, or dependence — the profile benzodiazepines fail on. Russian clinical work in generalised anxiety disorder and neurasthenia, notably the Zozulya group's trials, reported anxiolytic effect comparable to a benzodiazepine comparator without the accompanying sedation. Those trials were small and conducted in a single research ecosystem; "comparable to benzodiazepines" should be read as a finding from that body of work, not as an established equivalence.
Mechanistically, the best-documented single study is Volkova and colleagues (Frontiers in Pharmacology, 2016; 7:31), which profiled 84 neurotransmission-related genes in rat frontal cortex after a 300 µg/kg dose. Selank altered expression across a substantial share of them, correlating with GABA's own profile at one hour — but continued to produce transcriptional change at three hours, after GABA's effect had largely resolved. That temporal split is the argument that Selank is not simply a GABA mimetic but triggers a secondary cascade. Separate lines describe inhibition of enkephalin degradation and effects on serotonergic and dopaminergic signalling, plus immunomodulatory activity carried over from tuftsin.
Frame the choice by research endpoint, not by "which is stronger."
Semax fits work oriented toward neurotrophic signalling, neuroprotection after ischaemic insult, attention, and cognitive endpoints. It has the deeper human record, and the mechanistic story runs through BDNF.
Selank fits work oriented toward anxiety-like behaviour, stress reactivity, GABAergic and serotonergic pharmacology, and immune-neuroendocrine crosstalk. Its record is shallower but more targeted.
They overlap less than the marketing suggests. The Semax + Selank blend exists because the two are frequently paired in practice — but no controlled study characterises the combination, so a stacked protocol is an extrapolation from two separate literatures rather than something the data supports directly.
Both share the same practical constraints: minutes-long plasma presence, intranasal delivery as the studied route, and thin human pharmacokinetics. For handling and preparation, see the reconstitution guide and dosing math.
Is Semax or Selank the stronger nootropic? Neither has been tested against the other in a controlled head-to-head trial, so "stronger" has no measured answer. They address different endpoints: Semax's literature centres on neurotrophic and neuroprotective markers, Selank's on anxiolysis. Cross-study comparison cannot settle potency between them.
Are Semax and Selank the same class of peptide? No. Both are heptapeptides ending in Pro-Gly-Pro, but Semax derives from an ACTH melanocortin fragment and Selank from the immune peptide tuftsin. The shared C-terminal tail is a stability strategy, not a shared mechanism.
Why is almost all of the research Russian? Both compounds were developed and registered inside the Russian pharmaceutical system, and clinical development stayed there. Neither has been through FDA or EMA review, and independent replication outside that ecosystem is limited — which is the single biggest caveat on every efficacy claim made for either.
Can Semax and Selank be combined? They are frequently paired, and blended research material is sold on that basis. There is no controlled study of the combination, so any additive or synergistic effect is currently an assumption rather than a finding.
Why are half-lives measured in minutes if effects are described as lasting hours? Plasma clearance and duration of effect are different measurements. Both peptides are cleaved rapidly in circulation, but the Pro-Gly-Pro metabolite is itself active and the documented gene-expression changes outlast the parent molecule. Human pharmacokinetic data is thin enough that specific half-life figures should be treated as approximate.
